Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gracell Biotechnologies Inc.
Headquarters: Shanghai, China
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Nov 7, 2024
Politics, Policy & Law
Probe intensifies spotlight on AstraZeneca in China
Global pharmas and local biotechs weigh fallout of investigation into AZ China head
BioCentury | Jun 6, 2024
Product Development
Solid tumor immunotherapies headline ASCO’s first-in-human studies
A focus on first-in-class innovation and solid tumor applications
BioCentury | Apr 30, 2024
Management Tracks
Innovent hires Gracell vet Samuel Zhang as CBO
Plus: CEO changes at Lexicon, Avacta and Sphere Fluidics, and updates from Generate, Charm, ViaNautis and more
BioCentury | Jan 4, 2024
Finance
How TCG X will navigate evolving crossover dynamics with new $1B fund
Led by Chen Yu, firm launched in 2021 exceeds planned target for Fund II after string of M&A deals brings returns
BioCentury | Jan 4, 2024
Deals
Parsing premiums: 2023’s biopharma M&A deals
2023’s highest-premium takeouts and its top-value deal all came early, but 4Q was notable for its pace of $1B+ deals
BioCentury | Nov 29, 2023
Product Development
FDA’s CAR T safety concerns may put the modality’s future at risk
Agency is monitoring secondary T cell malignancies in patients treated with CAR T cells
BioCentury | Oct 5, 2023
Product Development
Innovation in autoimmune CAR Ts doesn’t stop at CD19
Dual targeting, allogeneic designs and novel targets are all under investigation to help CAR T cells reach more autoimmune patients
BioCentury | Sep 30, 2023
Product Development
CAR T’s next act: autoimmune diseases
CAR T developers exploring technologies and development paths to take the disruptive modality into new applications
BioCentury | Sep 28, 2023
Deals
Sept. 27 Quick Takes: Roche and Ionis taking another approach to Huntington disease
Plus: Venture financings for Avalyn, Sitryx and Singaporean newco Automera and updates from Biohaven, Ginkgo, Pfizer, Gilead and Gracell
Items per page:
1 - 10 of 39